Second Sight Medical Products (NASDAQ:EYES) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 15th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings results on Wednesday, March 13th. The medical device company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). Second Sight Medical Products had a negative net margin of 508.90% and a negative return on equity of 809.08%. The company had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.60 million. On average, analysts expect Second Sight Medical Products to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ EYES traded down $0.01 during trading hours on Thursday, reaching $0.94. 21,999 shares of the company were exchanged, compared to its average volume of 341,143. Second Sight Medical Products has a 1 year low of $0.63 and a 1 year high of $2.25. The company has a market capitalization of $119.29 million, a PE ratio of -1.80 and a beta of 2.30.
Separately, ValuEngine downgraded shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st.
TRADEMARK VIOLATION NOTICE: “Second Sight Medical Products (EYES) Scheduled to Post Quarterly Earnings on Wednesday” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2019/05/09/second-sight-medical-products-eyes-scheduled-to-post-quarterly-earnings-on-wednesday.html.
About Second Sight Medical Products
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma.
Featured Story: Technical Analysis
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.